This week, 12 Pharmaceuticals stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Catalent Inc (CTLT) slips from a C to a D this week. The company also gets F’s in earnings surprise and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CTLT stock.
Revance Therapeutics, Inc.’s (RVNC) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RVNC stock.
RedHill Biopharma Ltd. Sponsored ADR (RDHL) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RDHL stock.
Omeros Corporation (OMER) earns a D this week, moving down from last week’s grade of C. Omeros Corporation is a biopharmaceutical company developing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management. The company also gets F’s in earnings revisions, earnings surprise, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OMER stock.
This week, Flamel Technologies SA Sponsored ADR (FLML) drops from a C to a D rating. Flamel Technologies SA Sponsored ADR develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. The company also gets F’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of FLML stock.
Egalet Corporation (EGLT) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of EGLT stock.
This is a rough week for Cumberland Pharmaceuticals Inc. (CPIX). The company’s rating falls to F from the previous week’s D. Cumberland Pharmaceuticals Inc. engages in the acquisition, development, and commercialization of branded prescription products for the hospital acute care and gastroenterology markets primarily in the United States. The company also gets F’s in sales growth, operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CPIX stock.
Tetraphase Pharmaceuticals, Inc. (TTPH) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TTPH stock.
Corium International, Inc. (CORI) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CORI stock.
This week, Achaogen, Inc.’s (AKAO) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AKAO stock.
Slipping from a D to a F rating, Alimera Sciences, Inc. (ALIM) takes a hit this week. Alimera Sciences, Inc. engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company also gets F’s in earnings revisions and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALIM stock.
VIVUS, Inc. (VVUS) declines this week from a C to a D. VIVUS, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. The company also gets F’s in sales growth, earnings revisions, and free cash flow. For more information, get Portfolio Grader’s complete analysis of VVUS stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
